BTIG Enhances Healthcare Equity Research Team with Biotechnology Analyst Yun Zhong, PhD
“We are very pleased to welcome Yun to the BTIG Biotechnology Equity Research team,” noted Mr. Serwin. “Biotechnology continues to be one of the most active subsectors for clients of our healthcare practice. We believe that Yun’s decade of experience covering biotechnology companies makes him exceedingly qualified to help clients evaluate their investment opportunities in the space.”
Prior to BTIG, Dr. Zhong was a Biotech Equity Research Analyst at Berenberg Capital Markets. Previously, he was Director within Biotech Equity Research at Janney Montgomery Scott. Earlier in his career, Dr. Zhong was a Vice President within Biotech Equity Research at SunTrust Robinson Humphrey, and a Biotech Equity Research Associate at Cowen. He earned a PhD in molecular biology and neuroscience from Rockefeller University, as well as an MS and BS in biophysical engineering from Osaka University.
Dr. Zhong joins BTIG’s established team of publishing Biotechnology Analysts including Bert Hazlett, Thomas Shrader, PhD, CFA, Justin Zelin and Julian Harrison. Biotechnology continues to be a core area of growth for the firm which increasingly offers differentiated and actionable expertise for institutional and corporate clients.
BTIG Research and Strategy provides comprehensive reports, industry observations and other insights for clients. The team’s sector focus includes consumer, energy and infrastructure, financials, healthcare, real estate, as well as technology, media and telecommunications.
BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 650 employees, BTIG, LLC and its affiliates operate out of 19 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities (futures, interest rates, credit, as well as convertible and preferred securities). The firm’s core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more. Disclaimer: https://www.btig.com/disclaimer.